



Procedure for trial medication preparation if the patient has already received dexamethasone on the day of screening

If the patient has received 6.7 mg of intravenous (IV) dexamethasone (corresponding to 8 mg dexamethasone phosphate) or less OR

If the patient has received 8 mg of per oral (PO) dexamethasone or less

1. Stop the regular dexamethasone
2. Screen, randomise and administer trial medication to the patient today as follows:
 - a. If the patient is **randomised to 12 mg**: Administer bolus injection of **6 mg dexamethasone in isotonic saline (bolus volume 5 ml)**. Administer bolus injections of 12 mg dexamethasone for the remaining days of the intervention period.
 - b. If the patient is **randomised to 6 mg**: Administer **bolus injection of 5 ml isotonic saline only for this day**. Prepare and administer bolus injections of 6 mg dexamethasone for the remaining days of the intervention period.

If the patient has received more than 6.7 mg of IV dexamethasone (corresponding to 8 mg dexamethasone phosphate) or more than 8 mg of PO dexamethasone

1. Stop the regular dexamethasone
2. Screen the patient 12 h (or later) after the last administration of dexamethasone; if still eligible, randomise, prepare and administer trial medication to the patient then. Please beware that use of dexamethasone for 5 consecutive days or more is an exclusion criterion.

If your site uses another steroid for COVID-19 in clinical practice (e.g. methylprednisolone), please request a document specific for this drug.